CI
HRMY icon

Cordant Inc’s Harmony Biosciences HRMY Stock Holding History

Cordant Inc’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6
Closed – – 600
2022
Q1 		$0 Buy
+6
New +$245 ﹤0.01% 1291

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cordant Inc's HRMY Position: Q2 2022 in Review

Cordant Inc sold out of Harmony Biosciences (HRMY) in Q2 2022, closing a stake of 6 shares.

Cordant Inc first reported a position in HRMY in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 183 funds tracked by Wall St. Rank hold HRMY as of Q2 2022.

  • Cordant Inc reported no remaining Harmony Biosciences position as of Q2 2022 after selling out during the quarter.
  • Cordant Inc sold 6 Harmony Biosciences shares in Q2 2022.
  • Cordant Inc first reported a position in Harmony Biosciences in Q1 2022 and held it in 1 quarter.
  • Cordant Inc's Harmony Biosciences position peaked at $0 in Q1 2022.
  • 183 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2022.

Based on Cordant Inc's 13F filing for Q2 2022, filed 17 Aug 2022.